HalcyGen works on IND

By Dylan Bushell-Embling
Friday, 18 July, 2008

Generic drugs company HalcyGen Pharmaceuticals [ASX: HGN] has completed recruitment and dosing for the first of three pharmacokinetic trials of its SUBA-Itraconazole anti-fungal agent.

The trials, part of the company's Investigational New Drug (IND) application for the product, will examine the absorption, distribution, metabolism and excretion of SUBA-Itraconazole.

It will compare SUBA-Itraconazole directly to the itraconazole market-leader Sporanox, which was developed by Johnson and Johnson subsidiary Janssen Pharmaceuticals.

According to HalcyGen, early trials of SUBA-Itraconazole have already demonstrated increased bioavailability compared to Sporanox.

Related News

Accurate age estimation with DNA methylation

Using cutting-edge artificial intelligence, scientists created a tool that can determine a...

Algae unlocks a more ethical way to grow cells

Researchers have combined a new type of Queensland algae, Chlorella sp. BDH-1, with...

Oral drug shows promise for treating Barth syndrome

An oral drug called MA-5 can improve both heart and muscle problems in Barth syndrome, a rare...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd